Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?

키워드

참고문헌 (19)

1. Grace Lai-Hung Wong, "Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend", Clinical and Molecular Hepatology, 24(2), pp.108~113 (2018), 대한간학회
2. Mi Young Jeon, "Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B", Clinical and Molecular Hepatology, 27(2), pp.295~304 (2021), 대한간학회[DOI]
3. 홍영미, "만성 B형간염 면역관용기의 정의 및 치료", 대한소화기학회지, 79(4), pp.156~160 (2022), 대한소화기학회[DOI]
4. Kennedy PTF, "Immune tolerant chronic hepatitis B : The unrecognized risks", Viruses, 9, pp.96~ (2017)
5. Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
6. European Association for the Study of the Liver, "EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
7. Sarin SK, "Asian-Pacific clinical practice guidelines on the management of hepatitis B : a 2015 update", Hepatol Int, 10, pp.1~98 (2016)
8. Korean Association for the Study of the Liver (KASL), "KASL clinical practice guidelines for management of chronic hepatitis B", Clinical and Molecular Hepatology, 25(2), pp.93~159 (2019), 대한간학회
9. The Korean Association for the Study of the Liver, "KASL clinical practice guidelines for management of chronic hepatitis B", Clinical and Molecular Hepatology, 28(2), pp.276~331 (2022), 대한간학회
10. Kwo PY, "ACG Clinical guideline : Evaluation of abnormal liver chemistries", Am J Gastroenterol, 112, pp.18~35 (2017)
11. Lee HA, "Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase", Aliment Pharmacol Ther, 52, pp.196~204 (2020)
12. Jeong-Ju Yoo, "Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase", Clinical and Molecular Hepatology, 29(2), pp.482~495 (2023), 대한간학회
13. Lung-Yi Mak, "The role of different viral biomarkers on the management of chronic hepatitis B", Clinical and Molecular Hepatology, 29(2), pp.263~276 (2023), 대한간학회
14. Zhong S, "Cytokines and Chemokines in HBV Infection", Front Mol Biosci, 8, pp.805625~ (2021)
15. Bertoletti A, "The immune tolerant phase of chronic HBV infection : new perspectives on an old concept", Cell Mol Immunol, 12, pp.258~263 (2015)
16. Xing TJ, "MiRNA-548ah, a potential molecule associated with transition from immune tolerance to immune activation of chronic hepatitis B", Int J Mol Sci, 15, pp.14411~14426 (2014)
17. Lee HA, "Hepatitis B core-related antigen is useful for predicting phase and prognosis of hepatitis B e antigen-positive patients", J Clin Med, 11, pp.1729~ (2022)
18. Song G, "Serum HBV core-related antigen is a good predictor for spontaneous HBeAg seroconversion in chronic hepatitis B patients", J Med Virol, 89, pp.463~468 (2017)
19. Maasoumy B, "Hepatitis B core-related antigen(HBcrAg)levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D", Clin Microbiol Infect, 21, pp.606~ (2015)

관련 논문AI추천